(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

In a positive move, last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Eisai Co., Ltd (OTC: ESALY) and Biogen’s ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Nov 14 (Reuters) - The European Union's drugs regulator on Thursday recommended approval of Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi for some patients with early ...

Biogen has ducked out of a four-year-old collaboration with Karyopharm on a drug candidate for the neurodegenerative disease amyotrophic lateral sclerosis that could have been worth up to $217 ...

Investing.com -- KeyBanc Capital Markets downgraded Papa John’s International (PZZA) from Overweight to Sector Weight on Thursday, citing a prolonged path to recovery for the pizza chain.

So, Mattel has an ROCE of 13%. On its own, that's a standard return, however it's much better than the 11% generated by the Leisure industry.

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

An icon of 3 horizontal dots. An icon of a paper envelope. An icon of a facebook f logo. An icon of a digital camera. An icon of a house. An icon of the Instagram logo. An icon of the LinkedIn logo.

LONDON, Nov. 12, 2024 /PRNewswire/ -- With continued focus on the advancement of Anomaly's proposition in Europe, the company has announced the promotion of two long-term leaders tasked with ...

A slow launch for Alzheimer’s medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen’s shares down this year. Although it ...